Loading…
Regentis Biomaterials Ltd. is projected to rise to $2.14 by 2027, a +15% move from its current price of $1.87. RGNT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.69 | $1.87 | $2.07 | +0.06% |
| Aug 6 | $1.62 | $1.87 | $2.16 | +0.12% |
| Aug 7 | $1.57 | $1.87 | $2.23 | +0.18% |
| Aug 8 | $1.53 | $1.87 | $2.29 | +0.24% |
| Aug 9 | $1.50 | $1.88 | $2.35 | +0.30% |
| Aug 10 | $1.47 | $1.88 | $2.40 | +0.36% |
| Aug 11 | $1.44 | $1.88 | $2.45 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.44 | $1.88 | $2.45 | +0.42% |
| Week 2 | $1.29 | $1.89 | $2.75 | +0.84% |
| Week 3 | $1.19 | $1.89 | $3.00 | +1.26% |
| Week 4 | $1.12 | $1.90 | $3.24 | +1.69% |
| Week 5 | $1.05 | $1.91 | $3.46 | +2.11% |
| Week 6 | $0.9999 | $1.92 | $3.68 | +2.54% |
| Week 7 | $0.953 | $1.93 | $3.89 | +2.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Regentis Biomaterials Ltd. is a regenerative medicine company that develops and commercializes tissue repair solutions in the United States. It is based in Herzliya, Israel, and its portfolio includes Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
The company was incorporated in 2004 and operates in the Healthcare sector. Regentis focuses on advancing tissue repair solutions, leveraging its Gelrin platform and related offerings as part of its regenerative medicine strategy.
Regentis Biomaterials Ltd. (RGNT) is currently priced at $1.78 with a market capitalization of $12.5M and ranks 4,801 by market cap. This places it among small-cap healthcare names with niche regenerative medicine therapies.
The near-term price outlook is neutral to modestly constructive, with a 1-year forecast for 2026 showing an average of $1.78 and a range from $1.28 to $2.80. The forecast features a transition from neutral in the near term to more bullish dynamics later in the forecast window, including notable upside in the 2032–2050 period.
A major floor 31.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 144.4% above — a clean break opens room to run.
A major ceiling 402.7% above — clearing it would confirm fresh momentum.
Key RGNT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.83 | Buy | $1.83 | Buy |
| MA 10 | $1.91 | Sell | $2.01 | Sell |
| MA 20 | $2.54 | Sell | $2.39 | Sell |
| MA 50 | $2.87 | Sell | $2.79 | Sell |
| MA 100 | $2.87 | Sell | $3.24 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.79 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -77.96 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -28.40 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.63 | Sell |
| Awesome (5,34) | -1.50 | Sell |
| Ultimate (7,14,28) | 21.59 | Buy |
| Momentum (10) | -0.64 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.72 | Buy |
| ADX (14) | 18.24 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is Bearish. RSI14 is 40, and the price is below the 50-day simple moving average of $2.89, signaling lingering pressure in the near term.
Key support is identified at $1.50, with resistance at $9.40. The 30-day price range runs from a low of $0.8386 to a high of $3.78, highlighting ongoing volatility within a tight trading band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $1.87 | $2.96 | 0% | Neutral | |
| $1.41 | $2.14 | $3.52 | +15% | Neutral | |
| $1.15 | $1.93 | $3.47 | +3% | Neutral | |
| $1.12 | $2.08 | $3.97 | +11% | Neutral | |
| $0.8489 | $1.71 | $3.46 | -8% | Neutral | |
| $0.6973 | $1.53 | $3.23 | -18% | Bearish | |
| $1.02 | $2.28 | $4.99 | +22% | Bullish | |
| $1.14 | $2.54 | $5.78 | +36% | Bullish | |
| $1.19 | $2.65 | $6.11 | +42% | Bullish | |
| $1.18 | $2.62 | $6.02 | +40% | Bullish | |
| $1.68 | $3.72 | $8.56 | +99% | Bullish | |
| $1.98 | $4.40 | $10.13 | +135% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.28 | $1.87 | $2.58 | +0.00% |
| September 2026 | $1.62 | $2.02 | $2.68 | +8.23% |
| October 2026 | $1.54 | $1.97 | $2.69 | -2.43% |
| November 2026 | $1.58 | $2.06 | $2.87 | +4.43% |
| December 2026 | $1.57 | $2.08 | $2.96 | +1.06% |
Click any year to see its month-by-month RGNT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RGNT could reach as high as $2.96, with a base case around $1.87 and support toward $1.28 — roughly 0% from $1.87. Price action looks broadly range-bound.
Expect RGNT to range from $1.41 to $3.52 through 2027. The $2.14 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RGNT price prediction for 2028 points to an average of $1.93 (low $1.15, high $3.47) — a potential gain of +3% on today's $1.87. Price action looks broadly range-bound.
In 2029, RGNT is projected to trade between $1.12 and $3.97, averaging $2.08 — a potential gain of +11% from today's $1.87. That is up +7% on the projected 2028 average. A consolidation phase looks the most probable path here.
Regentis Biomaterials Ltd.'s 2030 outlook centres on $1.71, within a $0.8489 to $3.46 range. That is -17% versus the projected 2029 average. That marks a -8% change versus current levels. Price action looks broadly range-bound.
By 2031, RGNT could reach as high as $3.23, with a base case around $1.53 and support toward $0.6973 — roughly -18% from $1.87. Expect choppier, lower action through this leg of the cycle.
Expect RGNT to range from $1.02 to $4.99 through 2032. The $2.28 average target implies a +22% move from current prices. That is up +48% on the projected 2031 average. Momentum favours further upside here.
The RGNT price prediction for 2033 points to an average of $2.54 (low $1.14, high $5.78) — a potential gain of +36% on today's $1.87. Buyers look set to stay in control over this stretch.
In 2034, RGNT is projected to trade between $1.19 and $6.11, averaging $2.65 — a potential gain of +42% from today's $1.87. That is up +4% on the projected 2033 average. Momentum favours further upside here.
Regentis Biomaterials Ltd.'s 2035 outlook centres on $2.62, within a $1.18 to $6.02 range. That is -1% versus the projected 2034 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RGNT could reach as high as $8.56, with a base case around $3.72 and support toward $1.68 — roughly +99% from $1.87. Momentum favours further upside here.
Expect RGNT to range from $1.98 to $10.13 through 2050. The $4.40 average target implies a +135% move from current prices. That is up +18% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNT today (≈ 534.759358 RGNT) could be worth
$2,354.39
+$1,354.39 (+135%) by 2050 · US Dollar
Based on the average projected RGNT price of $4.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNTwould be worth at today's price.
$1,000 invested in RGNT on Dec 4, 2025 (≈ 133.333333 RGNT) would be worth
$249.33
-$750.67 (-75.1%) today · 0.25× · US Dollar
Based on a RGNT entry price of $7.5 vs. today's $1.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.96 | $954.08 | -4.6% |
| 1 month ago | $4.57 | $409.19 | -59.1% |
| 3 months ago | $2.87 | $651.57 | -34.8% |
| 6 months ago | $5.81 | $321.86 | -67.8% |
| All time ago | $7.5 | $249.33 | -75.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNT forecast.
Our base-case forecast reaches $3.70 around 2040.
Implied market cap at $3.70: $25.99M
The multi-year forecast shows a shift in sentiment from Neutral around 2026–2029 to Bearish in 2031, followed by a Bullish recovery from 2032 onward. The average price in 2030 is $1.62 with a -9.1% ROI, while 2031 shows a -16.7% ROI and Bearish sentiment. From 2032 through 2035, the averages rise (2032 $2.17, 2033 $2.43, 2034 $2.54, 2035 $2.47) with positive momentum, and ROIs of 21.7%, 36.4%, 42.7%, and 38.8% respectively.
The uptrend strengthens toward 2040 (avg $3.60, ROI 102%) and continues into 2050 (avg $4.10, ROI 130.3%). Max forecast values rise to $4.75 in 2032, $5.52 in 2033, $5.84 in 2034, $5.68 in 2035, $8.27 in 2040, and $9.43 in 2050, with sentiment turning Bullish from 2032 onward. These figures imply meaningful longer-term upside alongside the mid-term volatility and risk, reflecting a high-variance equity profile with substantial upside potential if the later-stage catalysts materialize.
Tap a question to reveal the answer.
Avg $1.62, min $0.8002, max $3.27; ROI -9.1%; sentiment Neutral.
Near term is Neutral (2026 avg $1.78) with a negative mid-term in 2030–2031 (-9.1% and -16.7% ROI, Bearish in 2031). Long term shows bullish potential with 2040 avg $3.60 (ROI 102%) and 2050 avg $4.10 (ROI 130.3%), indicating substantial upside but recognizing the mid-term risk and volatility.
Yes, the max forecast reaches $9.43 by 2050, with earlier year maxima such as $8.27 in 2040 and progressively higher levels in subsequent years.
For 2026, the min is $1.28, the avg is $1.78, and the max is $2.80; sentiment is Neutral.
Key near-term risks include negative ROI in 2030 (-9.1%) and 2031 (-16.7%), along with Bearish sentiment in 2031. The asset also shows high volatility (annualized volatility 200%), underscoring the potential for wide swings across the forecast. The longer-term scenario, while bullish, depends on future catalysts materializing as projected.
Regentis Biomaterials Ltd. Community Discussion
0Share your Regentis Biomaterials Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.